U.S. News Room
October 01, 2025
ENHERTU® Followed by THP Supplemental Biologics License Application Accepted in the US for Patients with High-Risk HER2 Positive Early-Stage Breast Cancer Prior to Surgery
Download
September 29, 2025
ENHERTU® Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Invasive Disease-Free Survival Versus T-DM1 in DESTINY-Breast05 Phase 3 Trial in Patients with High-Risk Early Breast Cancer Following Neoadjuvant Therapy
Download
September 24, 2025
ENHERTU® Plus Pertuzumab Granted Priority Review in the US as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
Download
September 15, 2025
Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab
Download